ThromboGenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps?

With U.S. sales of its eye drug Jetrea lagging, ThromboGenics is casting about for "strategic options." The company boasts Novartis' ($NVS) Alcon unit as a marketing partner outside the U.S. but has been going it alone in the States. Is another partnership in the offing? Release | Report